

[Sulfamethoxazole + trimethoprim](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.4. Antipneumocystosis and antitoxoplasmosis medicines](#)

ATC codes: [J01EE01](#)

EMLc

Indication

Pneumocystosis ICD11 code: [1F2G.Z](#)

INN

Sulfamethoxazole + trimethoprim

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Formulations

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule ; 80 mg + 16 mg per mL in 10 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc)

Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc)

EML status history

First added in 1997 ([TRS 882](#))

Changed in 2007 ([TRS 950](#))

Changed in 2011 ([TRS 965](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Sulfamethoxazole + trimethoprim](#)

DrugBank

[Sulfamethoxazole](#),

[Trimethoprim](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.